Fig. 1

Therapeutic regimens. No differences in terms of length of survival have been observed between cases treated with demethylating agents in comparison to 3 + 7 regimen (a). EFS was 32% at 12 months, and 19% at 24 months in the whole series; even in this case, patients enrolled in the GIMEMA trial showed a clear advantage, with 24 months-EFS of 65% versus 12% of the subjects receiving 3 + 7 and 8% of those receiving demethylating drugs (p < 0.001) (b)